Cellular Immune Responses in Mice Induced by M. tuberculosis PE35-DNA Vaccine Construct

Scandinavian Journal of Immunology

Volumn 74, Issue 6, 2011, Pages 554-560

  Hanif, S N M ^a   Al Attiyah, R ^a   Mustafa, A S ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; SYNTHETIC PEPTIDE;

ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL GENE; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; GENOMICS; HELPER CELL; MOLECULAR CLONING; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PE35 GENE; PRIORITY JOURNAL; RECOMBINANT PLASMID; SPLEEN CELL;

ANIMALS; BACTERIAL PROTEINS; BACTERIAL VACCINES; CELL PROLIFERATION; GENETIC VECTORS; MICE; MYCOBACTERIUM TUBERCULOSIS; VACCINES, DNA;

EID: 81255210309     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02604.x     Document Type: Article

References (52)

1. Global tuberculosis control: epidemiology, strategy, financing. WHO Report 2009 WHO/HTM/TB/2009.411.
2. Sander CM, McShane H. Translational mini-review series on vaccines: development and evaluation of improved vaccines against tuberculosis. Clin Exp Immunol 2007;147:401-11.
3. Maher D, Raviglione MC. The global epidemic of tuberculosis: A World Health Organization perspective. In: Schlossberg D, ed. tuberculosis and nontuberculous Mycobacterial Infections. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: WB Saunders Company, 1999:104-13.
4. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010;375:2110-9.
5. Aronson NE, Santosham M, Comstock GW et al. Long-term efficacy of BCG vaccine in American Indians and Alaska natives: A 60-year follow-up study. JAMA 2004;291:2086-91.
6. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005;3:656-62.
7. Mustafa AS, Al-Attiyah R. Tuberculosis: looking beyond BCG vaccines. J Postgrad Med 2003;49:134-40.
8. Hesseling AC, Schaaf HS, Hanekom WA. Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 2003;37:1226-33.
9. Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines 2008;7:635-50.
10. Beresford B, Sadoff JC. Update on research and development pipeline: tuberculosis vaccines. Clin Infect Dis 2010;3:S178-83.
11. Mustafa AS. Mycobacterial gene cloning and expression, comparative genomics, bioinformatics and proteomics in relation to the development of new vaccines and diagnostic reagents. Med Princ Pract 2005;14:27-34.
12. Mustafa AS. Vaccine potential of Mycobacterium tuberculosis-specific genomic regions: in vitro studies in humans. Expert Rev Vaccines 2009;8:1309-12.
13. Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284:1520-3.
14. Al-Attiyah R, Mustafa AS. Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG. Infect Immun 2008;76:4190-8.
15. Al-Attiyah R, Mustafa AS. Characterization of human cellular immune responses to Mycobacterium tuberculosis proteins encoded by genes predicted in RD15 genomic region that is absent in Mycobacterium bovis BCG. FEMS Immunol Med Microbiol 2010;59:177-87.
16. Hanif SN, El-Shammy AM, Al-Attiyah R, Mustafa AS. Whole blood assays to identify Th1 cell antigens and peptides encoded by Mycobacterium tuberculosis-specific RD1 genes. Med Princ Pract 2008;17:244-9.
17. Mustafa AS, Al-Attiyah R, Hanif SN, Shaban FA. Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells. Clin Vaccine Immunol 2008;15:916-24.
18. Hanif SN, Al-Attiyah R, Mustafa AS. Species-specific antigenic Mycobacterium tuberculosis proteins tested by delayed-type hypersensitivity response. Int J Tuberc Lung Dis 2010;14:489-94.
19. Mustafa AS. Cell mediated immunity assays identify proteins of diagnostic and vaccine potential from genomic regions of difference of Mycobacterium tuberculosis. Kuwait Med J 2010;42:98-105.
20. Ahmad S, Ali MM, Mustafa AS. Construction of a modified vector for efficient purification of recombinant Mycobacterium tuberculosis proteins expressed in Escherichia coli. Protein Expr Purif 2003;29:167-75.
21. Hanif SNM, Al-Attiyah R, Mustafa AS. Molecular cloning, expression, purification and immunological characterization of three low-molecular weight proteins encoded by genes in genomic regions of difference of Mycobacterium tuberculosis. Scand J Immunol 2010; 71:353-61.
22. Ahmad S, Amoudy HA, Thole JE, Young DB, Mustafa AS. Identification of a novel protein antigen encoded by a Mycobacterium tuberculosis-specific RD1 region gene. Scand J Immunol 1999;49:515-22.
23. Ahmad S, El-Shazly S, Mustafa AS, Al-Attiyah R. The six mammalian cell-entry proteins (Mce3A-F) are expressed during in vitro growth of Mycobacterium tuberculosis. Scand J Immunol 2005;62:16-24.
24. Ahmad S, El-Shazly S, Mustafa AS, Al-Attiyah R. Mammalian cell-entry proteins encoded by the mce3 operon of Mycobacterium tuberculosis are expressed during natural infection in humans. Scand J Immunol 2004;60:382-91.
25. Mustafa AS. Th1-cell reactivity and HLA-DR binding prediction for promiscuous recognition of MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis. Scand J Immunol 2009;69:213-22.
26. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44.
27. Hanif SN, Al-Attiyah R, Mustafa AS. DNA vaccine constructs expressing Mycobacterium tuberculosis- specific genes induce immune responses. Scand J Immunol 2010;72:408-15. In press
28. Mustafa AS. HLA-promiscuous Th1-cell reactivity of MPT64 (Rv1980c), a major secreted antigen of Mycobacterium tuberculosis, in healthy subjects. Med Princ Pract 2009;18:385-92.
29. Mustafa AS, Abal AT, Shaban F, El-Shamy AM, Amoudy HA. HLA-DR binding prediction and experimental evaluation of mycolyltransferase (Ag85B), a major secreted antigen of Mycobacterium tuberculosis. Med Princ Pract 2005;14:140-6.
30. Mustafa AS, Shaban FA. Propred analysis and experimental evaluation of promiscuous Th1 cell epitopes of three major secreted antigens of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2006;86:115-24.
31. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta analysis of the published literature. JAMA 1994;271:698-702.
32. Brewer TF. Preventing tuberculosis with Bacillus Calmette-Guerin vaccine: a meta analysis of the literature. Clin Infect Dis 2000;31:S64-7.
33. Fine PE. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989;11:S35-9.
34. Rodrigues LC, Diwan VK, Wheeler JC. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154-8.
35. Cardona PJ, Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis-latent bacilli. Eur Respir J 2004;24:1044-51.
36. Wiker HG, Mustafa T, Bjune GA, Harboe M. Evidence for waning of latency in a cohort study of tuberculosis. BMC Infect Dis 2010;23:10.
37. Bru A, Cardona PJ. Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice. PLoS ONE 2010;5:e12985.
38. Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 2009;37:80-6.
39. Huygen K. DNA vaccines against mycobacterial diseases. Future Microbiol 2006;1:63-73.
40. Romano M, Huygen K. DNA vaccines against mycobacterial diseases. Expert Rev Vaccines 2009;8:1237-50.
41. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 2006;12:216-21.
42. Okada M, Kita Y. Tuberculosis vaccine development: the development of novel (preclinical) DNA vaccine. Hum Vaccine 2010;6:297-308.
43. Baldwin SL, D'Souza CD, Orme IM et al. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and nonsecreted forms of Mycobacterium tuberculosis Ag85A. Tuber Lung Dis 1999;79:251-9.
44. Changhong S, Hai Z, Limei W et al. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene. Tuberculosis (Edinb) 2009;89:54-61.
45. Tian C, Jian-Ping X. Roles of PE_PGRS family in Mycobacterium tuberculosis pathogenesis and novel measures against tuberculosis. Microb Pathog 2010;49:311-4.
46. Delogu G, Brennan MJ. Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis. Infect Immun 2001;69:5606-11.
47. Mustafa AS. Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance. Tuberculosis (Edinb) 2005;85:367-76.
48. Chaitra MG, Shaila MS, Nayak R. Characterization of T-cell immunogenicity of two PE/PPE proteins of Mycobacterium tuberculosis. J Med Microbiol 2008;57:1079-86.
49. Vipond J, Vipond R, Allen-Vercoe E et al. Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge. Vaccine 2006;24:6340-50.
50. Rodrigues LC, Pereira SM, Cunha SS et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005;366:1290-5.
51. Roth AE, Benn CS, Ravn H. Cell mediated immunity assays identify proteins of diagnostic and vaccine potential from genomic regions of difference of Mycobacterium tuberculosis. BMJ 2010; 340:c671.
52. Fan X, Fu R. DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis infection in mice. Scand J Immunol 2007;66:523-8.